HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FTC Diagnoses Omicron Symptom: More Fraudulent COVID-19 Treatment Claims

Executive Summary

Agency says emergence of Omicron variant spurred marketers of products and services from peptide therapy to herbal remedies, and from nasal irrigation to intravenous drips to make false COVID-19 claims. 

You may also be interested in...

Michigan Firm’s Nasal Spray Neither A COVID-19 Treatment Nor For Nasal Use

CofixRx and Sensory Cloud are latest OTC nasal spray marketers FDA warned about fraudulent COVID-19 claims. While the others’ violations were limited to violative claims, CofixRx also warned the active ingredient in its spray is limited to topical use.

US Supplement Firm Touts COVID-19 Study, Kicks Off Promotional Campaign With Tae Bo Creator

Todos Medical, warned in 2021 about COVID-19 claims, could prompt a second warning about linking Tollovid  to the coronavirus with recent announcement of test results. Firm also has appointed VPs of marketing and of government affairs since FTC in April 2021 warned about claims on its website, its social media pages and in a store.

Health And Wellness Author's Farm Among US Businesses Warned About COVID-19 Claims

 FDA adds Soda Pharm of Ohio, Viraldine of New York and Bea Lydecker’s Naturals of Oregon to its list of businesses warned about sales of COVID-19- related products in violation of FDA regulations, which numbered 203 through 15 March.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts